scholarly journals Drug Resistance Reversal Potential of Nanoparticles/Nanocomposites via Antibiotic’s Potentiation in Multi Drug Resistant P. aeruginosa

Nanomaterials ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 117
Author(s):  
Pratima Pandey ◽  
Rajashree Sahoo ◽  
Khusbu Singh ◽  
Sanghamitra Pati ◽  
Jose Mathew ◽  
...  
Keyword(s):  
Zinc Oxide ◽  
Graphene Oxide ◽  
Reversal Potential ◽  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Drug Resistant ◽  
Mutant Prevention Concentration ◽  
Resistance Reversal ◽  
Synergistic Agent ◽  
Antibacterial Potential

Bacteria employ numerous resistance mechanisms against structurally distinct drugs by the process of multidrug resistance. A study was planned to discover the antibacterial potential of a graphene oxide nanosheet (GO), a graphene oxide–zinc oxide nanocomposite (GO/ZnO), a graphene oxide-chitosan nanocomposite (GO–CS), a zinc oxide decorated graphene oxide–chitosan nanocomposite (GO–CS/ZnO), and zinc oxide nanoparticles (ZnO) alone and in a blend with antibiotics against a PS-2 isolate of Pseudomonas aeruginosa. These nanocomposites reduced the MIC of tetracycline (TET) from 16 folds to 64 folds against a multidrug-resistant clinical isolate. Efflux pumps were interfered, as evident by an ethidium bromide synergy study with nanocomposites, as well as inhibiting biofilm synthesis. These nanoparticles/nanocomposites also decreased the mutant prevention concentration (MPC) of TET. To the best of our knowledge, this is the first report on nanomaterials as a synergistic agent via inhibition of efflux and biofilm synthesis.

Resistance to nitrofurantoin is an indicator of extensive drug-resistant (XDR) Enterobacteriaceae

2021 ◽  
Vol 70 (4) ◽  
Author(s):  
Balaram Khamari ◽  
Prakash Kumar ◽  
Bulagonda Eswarappa Pradeep
Keyword(s):  
Antimicrobial Agents ◽  
Efflux Pump ◽  
Treatment Options ◽  
Strong Association ◽  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Content Type ◽  
Link Type

Introduction. Nitrofurantoin is one of the preferred antibiotics in the treatment of uropathogenic multidrug-resistant (MDR) infections. However, resistance to nitrofurantoin in extensively drug-resistant (XDR) bacteria has severely limited the treatment options. Gap statement. Information related to co-resistance or collateral sensitivity (CS) with reference to nitrofurantoin resistant bacteria is limited. Aim. To study the potential of nitrofurantoin resistance as an indicator of the XDR phenotype in Enterobacteriaceae . Methods. One hundred (45 nitrofurantoin-resistant, 21 intermediately resistant and 34 nitrofurantoin-susceptible) Enterobacteriaceae were analysed in this study. Antibiotic susceptibility testing (AST) against nitrofurantoin and 17 other antimicrobial agents across eight different classes was performed by using the Vitek 2.0 system. The isolates were screened for the prevalence of acquired antimicrobial resistance (AMR) and efflux pump genes by PCR. Results. In total, 51 % of nitrofurantoin-resistant and 28 % of intermediately nitrofurantoin resistant isolates exhibited XDR characteristics, while only 3 % of nitrofurantoin-sensitive isolates were XDR (P=0.0001). Significant co-resistance was observed between nitrofurantoin and other tested antibiotics (β-lactam, cephalosporin, carbapenem, aminoglycoside and tetracycline). Further, the prevalence of AMR and efflux pump genes was higher in the nitrofurantoin-resistant strains compared to the susceptible isolates. A strong association was observed between nitrofurantoin resistance and the presence of bla PER-1, bla NDM-1, bla OXA-48, ant(2) and oqxA-oqxB genes. Tigecycline (84 %) and colistin (95 %) were the only antibiotics to which the majority of the isolates were susceptible. Conclusion. Nitrofurantoin resistance could be an indicator of the XDR phenotype among Enterobacteriaceae , harbouring multiple AMR and efflux pump genes. Tigecycline and colistin are the only antibiotics that could be used in the treatment of such XDR infections. A deeper understanding of the co-resistance mechanisms in XDR pathogens and prescription of AST-based appropriate combination therapy may help mitigate this problem.

scholarly journals Antibacterial activity of graphene oxide nanosheet against multidrug resistant superbugs isolated from infected patients

2020 ◽  
Vol 7 (7) ◽  
pp. 200640 ◽  
Author(s):  
Md. Toasin Hossain Aunkor ◽  
Topu Raihan ◽  
Shamsul H. Prodhan ◽  
H. S. C. Metselaar ◽  
Syeda Umme Fahmida Malik ◽  
...  
Keyword(s):  
Antibacterial Activity ◽  
Graphene Oxide ◽  
Antimicrobial Property ◽  
Multidrug Resistant ◽  
Diffusion Method ◽  
Drug Resistant ◽  
Graphene Nanosheet ◽  
Solid Agar ◽  
Good Biocompatibility ◽  
Agar Well Diffusion Method

Graphene oxide (GO) is a derivative of graphene nanosheet which is the most promising material of the decade in biomedical research. In particular, it has been known as an antimicrobial nanomaterial with good biocompatibility. In this study, we have synthesized and characterize GO and checked its antimicrobial property against different Gram-negative and Gram-positive multidrug drug resistant (MDR) hospital superbugs grown in solid agar-based nutrient plates with and without human serum through the utilization of agar well diffusion method, live/dead fluorescent staining and genotoxicity analysis. No significant changes in antibacterial activity were found in these two different conditions. We also compare the bactericidal capability of GO with some commonly administered antibiotics and in all cases the degree of inhibition is found to be higher. The data presented here are novel and show that GO is an effective bactericidal agent against different superbugs and can be used as a future antibacterial agent.

scholarly journals In vivo emergence of resistance to cefiderocol in an XDR Pseudomonas aeruginosa and an MDR Citrobacter koseri after prolonged therapy: a case report.

2020 ◽  
Author(s):  
Carolina Grande Perez ◽  
Evelyne Maillart ◽  
Véronique Yvette Miendje Deyi ◽  
Te Din Daniel Huang ◽  
Prochore Kamgang ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Resistant Bacteria ◽  
Drug Resistant ◽  
Class A ◽  
Stewardship Program ◽  
Class D ◽  
Emergence Of Resistance

Abstract The non-fermenters, e.g. Pseudomonas aeruginosa, and the extended spectrum β-lactamases or carbapenemases producing enterobacteriaceae represent a serious threat for patients admitted in Intensive Care Units (ICUs). News antibiotics have been developed to treat multidrug resistant bacteria. However, treatment emerging resistance has been shown for many of these newest antibiotics. Cefiderocol, a siderophore-antibiotic, has been developed to overcome most of the resistance mechanisms and shows great efficacy against most multi-drug resistant and extensively drug resistant Gram-negative bacteria, including the non-fermenters. We report the case of a patient abundantly treated with antibiotics. He received 158 days of antibiotherapy on 230 hospitalization days, including a six-week course of cefiderocol, in 14 different treatment lines. The patient developed a Pseudomonas aeruginosa (MIC: 8 µg/ml, GES type ESBL) and a Citrobacter koseri (MIC: 16 µg/ml, CTX-M group 9 type class A β-lactamase and a class D OXA-1 oxacillinase) resistant to cefiderocol. This antibiotic should be used with caution to preserve its efficacy, within a strict antimicrobial stewardship program.

scholarly journals Targeting the bacterial SOS response for new antimicrobial agents: drug targets, molecular mechanisms and inhibitors

2021 ◽  
Author(s):  
Thomas Lanyon-Hogg
Keyword(s):  
Drug Targets ◽  
Molecular Mechanisms ◽  
Antimicrobial Agents ◽  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Structure And Function ◽  
Drug Resistant ◽  
Target Validation ◽  
Sos Pathway ◽  
And Function

Antimicrobial resistance is a pressing threat to global health, with multidrug-resistant pathogens becoming increasingly prevalent. The bacterial SOS pathway functions in response to DNA damage that occurs during infection, initiating several pro-survival and resistance mechanisms, such as DNA repair and hypermutation. This makes SOS pathway components potential targets that may combat drug-resistant pathogens and decrease resistance emergence. This review discusses the mechanism of the SOS pathway; the structure and function of potential targets AddAB, RecBCD, RecA and LexA; and efforts to develop selective small-molecule inhibitors of these proteins. These inhibitors may serve as valuable tools for target validation and provide the foundations for desperately needed novel antibacterial therapeutics.

Comparative Drug Resistance Reversal Potential of Natural Glycosides: Potential of Synergy Niaziridin & Niazirin

2019 ◽  
Vol 19 (10) ◽  
pp. 847-860 ◽  
Author(s):  
Gaurav R. Dwivedi ◽  
Anupam Maurya ◽  
Dharmendra K. Yadav ◽  
Feroz Khan ◽  
Mahendra K. Gupta ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Expression Pattern ◽  
Moringa Oleifera ◽  
Efflux Pump ◽  
Reversal Potential ◽  
Drug Resistant ◽  
Reversal Agent ◽  
Efflux Pump Inhibition ◽  
In Silico Studies ◽  
Resistance Reversal

Background: Due to the limited availability of antibiotics, Gram-negative bacteria (GNB) acquire different levels of drug resistance. It raised an urgent need to identify such agents, which can reverse the phenomenon of drug resistance. Objective: To understand the mechanism of drug resistance reversal of glycosides; niaziridin and niazirin isolated from the pods of Moringa oleifera and ouabain (control) against the clinical isolates of multidrug-resistant Escherichia coli. Methods: The MICs were determined following the CLSI guidelines for broth micro-dilution. In-vitro combination studies were performed by broth checkerboard method followed by Time-Kill studies, the efflux pump inhibition assay, ATPase inhibitory activity, mutation prevention concentration and in-silico studies. Results: The results showed that both glycosides did not possess antibacterial activity of their own, but in combination, they reduced the MIC of tetracycline up to 16 folds. Both were found to inhibit efflux pumps, but niaziridin was the best. In real time expression pattern analysis, niaziridin was also found responsible for the down expression of the two important efflux pump acrB & yojI genes alone as well as in combination. Niaziridin was also able to over express the porin forming genes (ompA & ompX). These glycosides decreased the mutation prevention concentration of tetracycline. Conclusion: This is the first ever report on glycosides, niazirin and niaziridin acting as drug resistance reversal agent through efflux pump inhibition and modulation of expression pattern drug resistant genes. This study may be helpful in preparing an effective antibacterial combination against the drug-resistant GNB from a widely growing Moringa oleifera.

scholarly journals Drug Resistance Mechanisms in Tuberculosis

2020 ◽  
Author(s):  
Lanfranco Fattorini ◽  
Angelo Iacobino ◽  
Federico Giannoni
Keyword(s):  
Drug Resistance ◽  
Molecular Mechanisms ◽  
Drug Distribution ◽  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Diagnostic Methods ◽  
Drug Resistant ◽  
Resistance Development ◽  
Intrinsic Drug Resistance ◽  
Incident Cases

The increased incidence of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, defined as resistant to at least isoniazid and rifampin, the two highly bactericidal first-line drugs, is a major concern for tuberculosis (TB) control. The worldwide estimate of almost half a million incident cases of MDR/rifampin-resistant TB, is causing increasing concern. In this view, it is important to continuously update the knowledge on the mechanisms involved in the development of drug-resistant TB. Clinical, biological and microbiological reasons account for the generation of resistance, including: (i) nonadherence of patients to their therapy, and/or errors of physicians in therapy management, (ii) complexity and poor vascularization of granulomatous lesions, which obstruct drug distribution to some sites, resulting in resistance development, (iii) intrinsic drug resistance of tubercle bacilli, (iv) formation of non-replicating, drug-tolerant bacilli inside the granulomas, (v) development of mutations in Mtb genes, which are the most important molecular mechanisms of resistance. Here, a piece of information on the interplay of these factors is provided, to facilitate the clinical and microbiological management of drug-resistant TB at the global level, with attention also to the most recent diagnostic methods.

An overview of zinc oxide nanoparticles produced by plant extracts for anti-tuberculosis treatments

2021 ◽  
Vol 28 ◽  
Author(s):  
Farahnaz Behzad ◽  
Erfan Sefidgar ◽  
Azam Samadi ◽  
Wensen Lin ◽  
Iman Pouladi ◽  
...  
Keyword(s):  
Zinc Oxide ◽  
Plant Extracts ◽  
Zinc Oxide Nanoparticles ◽  
Herbal Medicines ◽  
Multidrug Resistant ◽  
Oxide Nanoparticles ◽  
Drug Resistant ◽  
Cure Rate ◽  
Zno Nps ◽  
Tb Treatment

: Tuberculosis (TB), induced by Mycobacterium tuberculosis (MTB), is a fatal infectious disease that kills millions of lives worldwide. The emergence of drug-resistant and multidrug-resistant cases is regarded as one of the most challenging threats to TB control due to the low cure rate. Therefore, TB and drug-resistant TB epidemics urge us to explore more effective therapies. The increasing knowledge of nanotechnology has extended to some nanomedicines for disease treatment in the clinic, which also provides novel possibilities for nano-based medicines for TB treatment. Zinc oxide nanoparticles (ZnO NPs) have gained increasing attention for anti-bacterial uses based on their strong ability to induce reactive oxidative species (ROS) and release bactericidal Zinc ions (Zn2+), which are expected to act as novel strategies for TB and drug-resistant TB treatment. Some active herbal medicines from plant extracts have been widely reported to show attractive anti-bacterial activity for infectious treatment, including TB. Here, we summarize the synthesis of ZnO NPs using plant extracts (green synthesized ZnO NPs) and further discuss their potentials for anti-TB treatments. This is the first review article discussing the anti–TB activity of ZnO NPs produced using plant extracts, which might contribute to the further applications of green synthesized ZnO NPs for anti-TB and drug-resistant TB treatment.

Sign in / Sign up

Export Citation Format

Share Document